Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SensoLyte® Rh110 Factor Xa Assay Kit

FRET Fluorometric
Catalog No. ABIN1882458
  • Target See all Factor Xa (FXa) Kits
    Factor Xa (FXa) (Activated Coagulation Factor X (FXa))
    Detection Method
    Fluorometric
    Application
    Fluorescence Resonance Energy Transfer Microscopy (FRET)
    Brand
    SensoLyte®
    Characteristics
    The SensoLyte® Rh110 Factor Xa Assay Kit provides a convenient assay for screening of FXa inhibitors or continuous assay of enzyme activity using a fluorogenic substrate. Upon FXa protease cleavage, this substrate generates the Rh110 (rhodamine 110) fluorophore which has a bright green fluorescence that can be detected at excitation/emission=490 nm/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from other reaction components.
    Top Product
    Discover our top product FXa ELISA Kit
  • Comment

    FRET-based Assay Kit

    Restrictions
    For Research Use only
  • Handling Advice
    Protect Components A and B from light and moisture.
    Storage
    -80 °C
    Storage Comment
    Store all kit components at -20 °C, except for Component C. Store Component C at -80 °C. Component D can be stored at room temperature for convenience
  • Target
    Factor Xa (FXa) (Activated Coagulation Factor X (FXa))
    Alternative Name
    Factor Xa (FXa Products)
    Synonyms
    FX Kit, FXA Kit, coagulation factor X Kit, F10 Kit
    Background
    Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex. FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation. In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets. FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.
You are here:
Support